Roflumilast - AstraZeneca

Drug Profile

Roflumilast - AstraZeneca

Alternative Names: APTA-2217; B 9302-107; BY 217; BYK 20869; Daliresp; Daxas; IN-ALR 01; Libertek

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALTANA Pharma
  • Developer Actavis; Almirall S.A.; AstraZeneca; Mitsubishi Tanabe Pharma Corporation; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Aminopyridines; Antiallergics; Antiasthmatics; Benzamides; Cyclopropanes; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Discontinued Alzheimer's disease; Asthma; Atopic dermatitis; Non-alcoholic steatohepatitis; Plaque psoriasis; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 18 May 2018 Pharmacodynamics data from a phase III trial in Chronic obstructive pulmonary disease presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 05 Apr 2018 Discontinued - Phase-I for Alzheimer's disease (Combination therapy, In volunteers) in United Kingdom (PO)
  • 05 Apr 2018 Discontinued - Phase-I for Plaque psoriasis in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top